CRMD, CELC, RANI, and RAPT are pushing aggressively to the upside on Monday. Here's what is driving these four biotech stocks ...

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data ...

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and ...

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic. Click here for ...

In a market environment where low interest rates have become the norm, income-focused investors are increasingly turning to ...

Get the latest Stock-picks news, photos, videos, and podcasts. Explore more for Stock-picks breaking news, opinions, special reports, and more on mint.

Danaher Corporation’s DHR Biotechnology segment continues to play an important role in its overall growth. In the second quarter of 2025, the segment’s core revenues rose 6% on a year-over-year basis, ...